Want to see SANA full AI Analyst Report?
Sana Biotechnology (SANA) Ratios
Sana Biotechnology Ratios
SANA's free cash flow for Q2 2026 was $-34.41M. For the 2026 fiscal year, SANA's free cash flow was decreased by $-1.62M and operating cash flow was $-32.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 |
| Quick Ratio | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 |
| Cash Ratio | 0.91 | 2.81 | 2.07 | 1.59 | 2.55 |
| Solvency Ratio | -0.90 | -1.00 | -0.93 | -0.78 | -0.86 |
| Operating Cash Flow Ratio | -1.83 | -4.91 | -3.93 | -2.60 | -2.53 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -107.33M | $ -89.71M | $ -64.28M | $ 121.03M | $ 157.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.19 | 0.18 | 0.13 | 0.10 |
| Debt-to-Equity Ratio | 0.49 | 0.38 | 0.36 | 0.22 | 0.15 |
| Debt-to-Capital Ratio | 0.33 | 0.27 | 0.27 | 0.18 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.59 | 2.00 | 1.97 | 1.65 | 1.55 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.31 | 0.41 | 0.54 | 0.57 | 0.67 |
| Net Debt to EBITDA | -0.03 | 0.13 | 0.11 | 0.27 | 0.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 127.86% | 97.81% | 96.63% | 98.87% | 99.73% |
| Return on Assets (ROA) | -58.57% | -53.24% | -50.11% | -32.75% | -31.51% |
| Return on Equity (ROE) | -151.77% | -106.49% | -98.52% | -53.97% | -48.86% |
| Return on Capital Employed (ROCE) | -56.47% | -59.86% | -58.53% | -38.32% | -34.65% |
| Return on Invested Capital (ROIC) | -54.08% | -58.26% | -57.03% | -37.67% | -34.34% |
| Return on Tangible Assets | -112.48% | -88.57% | -77.50% | -43.26% | -38.29% |
| Earnings Yield | -23.69% | -70.88% | -35.69% | -36.22% | -13.82% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 7.64 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -47.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 47.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.57 | -0.97 | -1.30 | -1.54 | -1.51 |
| Free Cash Flow Per Share | -0.57 | -1.11 | -1.41 | -1.65 | -1.69 |
| Dividend Paid and CapEx Coverage Ratio | -153.33 | -6.68 | -12.66 | -13.89 | -8.41 |
| Capital Expenditure Coverage Ratio | -153.33 | -6.68 | -12.66 | -13.89 | -8.41 |
| Operating Cash Flow Coverage Ratio | -1.82 | -2.37 | -2.44 | -2.68 | -2.26 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -14.05% | -68.18% | -34.47% | -41.79% | -10.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.24 | -1.41 | -2.80 | -2.76 | -7.24 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.41 | 1.50 | 2.76 | 1.49 | 3.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.12 | -1.47 | -2.90 | -2.39 | -9.17 |
| Price-to-Operating Cash Flow Ratio | -7.17 | -1.69 | -3.13 | -2.56 | -10.26 |
| Price-to-Earnings Growth (PEG) Ratio | 0.25 | 0.07 | -1.34 | 0.08 | -0.23 |
| Enterprise Value Multiple | -4.48 | -1.38 | -2.85 | -2.63 | -7.04 |
| Enterprise Value | 1.04B | 342.98M | 764.31M | 675.45M | 2.43B |
| EV to EBITDA | -4.48 | -1.38 | -2.85 | -2.63 | -7.04 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.17 | -1.34 | -2.79 | -2.17 | -8.67 |
| EV to Operating Cash Flow | -7.21 | -1.54 | -3.01 | -2.33 | -9.70 |
| Tangible Book Value Per Share | -0.15 | 0.22 | 0.45 | 1.59 | 3.18 |
| Shareholders’ Equity Per Share | 0.64 | 1.08 | 1.48 | 2.65 | 4.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.97 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.59 | 0.84 | 0.90 | 1.08 | 0.71 |
Currency in USD